Neurocrine Biosciences Inc vs TD SYNNEX Corporation Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $136.25 (market cap $13.82B), while TD SYNNEX Corporation Common Stock trades at $255 (market cap $21.04B). The key difference: TD SYNNEX Corporation Common Stock is the larger of the two by market cap, and TD SYNNEX Corporation Common Stock pays a 0.73% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 24 Days and TD SYNNEX Corporation Common Stock for 0 Days on average.
| NBIX | SNX | |
|---|---|---|
Market Cap | $13.82B | $21.04B |
Volume | 1,506,669 | 641,037 |
Sector | Health | Technology |
52-Week High | $185.50 | $290.14 |
52-Week Low | $123.10 | $142.42 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $13.83B | $25.81B |
Dividend Yield | — | 0.73% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →TD SYNNEX Corporation is a global IT distributor and solutions aggregator that distributes endpoint devices and data-center technologies from technology vendors to resellers and customers worldwide.
Read more on SNX →